CHRI second quarter revenues increase to $8 million China Health Source.

‘CHRI achieved excellent results in the second one fourth,’ observed Jiayin Wang, CHRI’s Chairman and CEO. ‘Orders in the one fourth were up almost 80 percent with an elevated gross and net margin from 18 percent to 32 percent and 10 percent to 21 percent, respectively. This order power translated into strong top-line performance and improved product margins which, in conjunction with a well maintained low priced of operating structure relatively, drove earnings significantly above our goals’, noted Mr. Wang. ‘Many reasons contributed to the strong performance in net income for the first six months of 2011. First, there’s been a rise in revenue from a higher volume of sales of natural Dahurian Angelica Root . Furthermore, CHRI has other new products making solid headway including Rhizoma Gastrodiae, or ‘TianMa’, through distinctive agreements with Chinese suppliers.Participants underwent both high-quality MR imaging of mind structure and Family pet scanning with PiB to identify amyloid plaques. The results showed that those cognitively regular individuals who acquired amyloid plaques also had structural changes similar to but much less pronounced than the neurodegenerative changes observed in the symptomatic individuals. Structural changes were most evident in areas comprising what is known as the default network, which is known to be affected early in the course of Alzheimer’s disease.